Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden, explains that plasma p-tau markers appear to be more indicative of amyloid traces than tau pathology specifically, highlighting the need for discovery of blood biomarkers that solely indicate tau pathology. He also highlights how some plasma biomarkers, like neurofilament light chain, can also have increased levels caused by other diseases and are impacted by numerous biological variables, so widespread clinical introduction as markers for Alzheimer’s disease would come with significant education requirements. This interview took place at the AP/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
